Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains

Journal of Virology

Volumn 90, Issue 5, 2016, Pages 2544-2550

  Ryder, Alex B ^a   Nachbagauer, Raffael ^b,c   Buonocore, Linda ^a   Palese, Peter ^b   Krammer, Florian ^b   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC HEMAGGLUTININ; CHIMERIC PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG; VESICULOVIRUS VECTOR; VIRUS ANTIBODY; VIRUS VECTOR; DRUG CARRIER; INFLUENZA VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG DOSAGE FORM COMPARISON; HUMORAL IMMUNITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL RATE; VESICULOVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BODY WEIGHT; DISEASE MODEL; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SURVIVAL ANALYSIS; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; CROSS REACTIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SYNTHETIC; VESICULOVIRUS;

EID: 84959382537     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02598-15     Document Type: Article

References (28)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340. http://dx.doi.org/10.1001/jama.292.11.1333.
2. McLean HQ, Meece JK, Belongia EA. 2014. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness. Vaccine 32:453-457. http://dx.doi.org/10.1016/j.vaccine.2013.11.060.
3. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11)70295-X.
4. Centers for Disease Control and Prevention. 2015. Measles vaccination. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/measles/vaccination.html.
5. Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N. 2012. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 11:CD008521.
6. Zajac BA, West DJ, McAleer WJ, Scolnick EM. 1986. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 13(Suppl A):39-45. http://dx.doi.org/10.1016/S0163-4453(86)92668-X.
7. Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, Colborn DK, Kurs-Lasky M, Haralam MA, Byers CJ, Zoffel LM, Fabian IA, Bernard BS, Kerr JD. 2003. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 290:1608-1616.
8. Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, Abrutyn E. 2002. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 37:427-439. http://dx.doi.org/10.1016/S0531-5565(01)00210-8.
9. Wright PF, Kawaoka Y. 2007. Orthomyxoviruses, p 1691-1740. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott/Williams & Wilkins, Philadelphia, PA.
10. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, Garcia-Sastre A, Palese P. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad SciUSA109:2573-2578. http://dx.doi.org/10.1073/pnas.1200039109.
11. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86:5774-5781. http://dx.doi.org/10.1128/JVI.00137-12.
12. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13.
13. Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, Garcia-Sastre A, Albrecht RA. 2014. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88:3432-3442. http://dx.doi.org/10.1128/JVI.03004-13.
14. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, Garcia-Sastre A, Palese P. 2013. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87:10435-10446. http://dx.doi.org/10.1128/JVI.01715-13.
15. Goff PH, Eggink D, Seibert CW, Hai R, Martinez-Gil L, Krammer F, Palese P. 2013. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8:e79194. http://dx.doi.org/10.1371/journal.pone.0079194.
16. Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, Chen D, Palese P. 2014. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 88:2340-2343. http://dx.doi.org/10.1128/JVI.03183-13.
17. Rose NF, Roberts A, Buonocore L, Rose JK. 2000. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74:10903-10910. http://dx.doi.org/10.1128/JVI.74.23.10903-10910.2000.
18. Schwartz JA, Buonocore L, Roberts A, Suguitan A, Jr, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK. 2007. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce crossneutralizing antibodies and long-term protection. Virology 366:166-173. http://dx.doi.org/10.1016/j.virol.2007.04.021.
19. Schwartz JA, Buonocore L, Suguitan AL, Jr, Silaghi A, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK. 2010. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol 84:4611-4618. http://dx.doi.org/10.1128/JVI.02637-09.
20. Ryder AB, Buonocore L, Vogel L, Nachbagauer R, Krammer F, Rose JK. 2015. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol 89:2820-2830. http://dx.doi.org/10.1128/JVI.03246-14.
21. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, Albrecht R, Perez DR, Garcia-Sastre A, Palese P. 2009. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83:1742-1753. http://dx.doi.org/10.1128/JVI.01920-08.
22. Lawson ND, Stillman EA, Whitt MA, Rose JK. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92:4477-4481. http://dx.doi.org/10.1073/pnas.92.10.4477.
23. Schnell MJ, Johnson JE, Buonocore L, Rose JK. 1997. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90:849-857. http://dx.doi.org/10.1016/S0092-8674(00)80350-5.
24. Fuerst TR, Niles EG, Studier FW, Moss B. 1986. Eukaryotic transientexpression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A 83:8122-8126. http://dx.doi.org/10.1073/pnas.83.21.8122.
25. Margine I, Palese P, Krammer F. 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 81: e51112. http://dx.doi.org/10.3791/51112.
26. Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A. 2013. Evaluation of mucosal and systemic immune responses elicited by GPI-0100-adjuvanted influenza vaccine delivered by different immunization strategies. PLoS One 8:e69649. http://dx.doi.org/10.1371/journal.pone.0069649.
27. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. 2014. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88:13260-13268. http://dx.doi.org/10.1128/JVI.02133-14.
28. Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, Garcia-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R. 2014. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 111:13133-13138. http://dx.doi.org/10.1073/pnas.1414070111.